Germline PTPRD Mutations in ewing sarcoma: Biologic and clinical implications

Oncotarget

Volumn 4, Issue 6, 2013, Pages 884-889

  Jiang, Yunyun ^a   Janku, Filip ^a   Subbiah, Vivek ^a   Angelo, Laura S ^a   Naing, Aung ^a   Anderson, Peter M ^a   Herzog, Cynthia E ^a   Fu, Siqing ^a   Benjamin, Robert S ^a   Kurzrock, Razelle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Ewing sarcoma; Germline; Mutation; PTPRD

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE DELTA; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; STAT3 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; DISEASE COURSE; EWING SARCOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; PROGRESSION FREE SURVIVAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; SARCOMA, EWING; STAT3 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84880823765     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1021     Document Type: Article

References (23)

1. Claus EB, Schildkraut JM, Thompson WD and Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77(11):2318-2324.
2. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B and Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68(3):700-710.
3. Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol. 2001; 119(11):1699-1704.
4. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-1238.
5. Burchill SA. Molecular abnormalities in Ewing's sarcoma. Expert Rev Anticancer Ther. 2008; 8(10):1675-1687.
6. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA and Juergens H. Ewing's sarcoma family of tumors: current management. Oncologist. 2006; 11(5):503-519.
7. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene. 2005; 363:1-14.
8. Lai R, Navid F, Rodriguez-Galindo C, Liu T, Fuller CE, Ganti R, Dien J, Dalton J, Billups C and Khoury JD. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol. 2006; 208(5):624-632.
9. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003; 197(2):157-168.
10. Julien SG, Dube N, Hardy S and Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011; 11(1):35-49.
11. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A. 2009; 106(23):9435-9440.
12. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N and Baylin SB. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008; 5(5):e114.
13. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y and Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 2008; 68(24):10300-10306.
14. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD and Gore L. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010; 16(8):2458-2465.
15. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA and Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012; 18(9):2625-2631.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228-247.
17. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P and Kurzrock R. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011; 6(4):e18424.
18. Naing A, Lorusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA and Kurzrock R. Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. Clin Cancer Res. 2012 ;18(9):2625-31.
19. Subbiah V and Kurzrock R. Ewing's sarcoma: overcoming the therapeutic plateau. Discov Med. 2012; 13(73):405-415.
20. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C and LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011; 17(18):6052-6060.
21. Exome Variant Servier [cited 2012 09/19]; Available from: http://evs.gs.washington.edu/EVS/.
22. Catalogue of Somatic Mutations in Cancer [cited 2012 09/19]; Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic/
23. Zhang W, Zong CS, Hermanto U, Lopez-Bergami P, Ronai Z and Wang LH. RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorageindependent growth. Mol Cell Biol. 2006; 26(2):413-424.